Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
SGLT2 inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2017 |
| gptkbp:ATCCode |
A10BK04
|
| gptkbp:brand |
gptkb:Steglatro
|
| gptkbp:chemicalFormula |
C22H25ClO7
|
| gptkbp:contraindication |
type 1 diabetes
severe renal impairment |
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Merck_&_Co. |
| gptkbp:eliminationHalfLife |
about 16 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
ertugliflozin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits sodium-glucose co-transporter 2 (SGLT2)
|
| gptkbp:metabolism |
gptkb:UGT1A9
gptkb:UGT2B7 |
| gptkbp:molecularWeight |
432.88 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
genital mycotic infection increased urination |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:Steglatro
|
| gptkbp:bfsLayer |
5
|